Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Slides:

Advertisements

Similar presentations

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation Li Mei Poon, Amir Hamdi, Rima.

Advertisements

Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed.

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation Li Mei Poon, Amir Hamdi, Rima.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction Muzaffar H. Qazilbash, Ali Imran.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.

Clofarabine ± Fludarabine with Once Daily i. v

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era Sarah F. Keller,

Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation by Takuya Sekine,

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis Nina.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.

Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma Gaurav C. Parikh, Ali Imran Amjad, Rima.

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission Betul Oran, Uday.

Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Ankur Varma,

Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning Yvette L. Kasamon,

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia Fleur M. Aung,

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning.

Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.

The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation Rohtesh S. Mehta, Antonio Di Stasi, Borje S.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma Christopher Parrish, Amin Rahemtulla, Jim.

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Koji Sasaki, Gary Lu, Rima M. Saliba,

Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with.

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing.

Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation Koji Sasaki, MD, Rima Saliba, PhD, Gary.

Biology of Blood and Marrow Transplantation

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic.

Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center Sai Ravi.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Carlos A. Ramos, Rima.

Myeloablative Reduced-Toxicity i. v

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.

Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML Uday R. Popat, MD, Rima Saliba, PhD, Betul Oran, MD, Julianne Chen, BS, Amin.

Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma.

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous.

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients Mithun Vinod Shah, Rima M.

Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan- Based Conditioning Jonathan E. Brammer, Issa Khouri, Sameh Gaballa,

Muzaffar H. Qazilbash, Rima M

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation Stefan O. Ciurea,

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Daniel R Couriel,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin.

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:

Once Daily i. v. Busulfan and Fludarabine (i. v

Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma Philip A. Thompson, MBBS, FRACP, FRCPA,

Presentation transcript:

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome Yago Nieto, Uday Popat, Paolo Anderlini, Ben Valdez, Borje Andersson, Ping Liu, Chitra Hosing, Elizabeth J. Shpall, Amin Alousi, Partow Kebriaei, Muzaffar Qazilbash, Simrit Parmar, Qaiser Bashir, Nina Shah, Issa Khouri, Gabriela Rondon, Richard Champlin, Roy B. Jones Biology of Blood and Marrow Transplantation Volume 19, Issue 3, Pages 410-417 (March 2013) DOI: 10.1016/j.bbmt.2012.10.029 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Outcomes of cohorts of patients with refractory HL treated with Gem-Bu-Mel, Bu-Mel, or BEAM (2005-2010). (A) EFS of the 3 groups. (B) EFS of Gem-Bu-Mel versus the combined Bu-Mel + BEAM groups (log-rank: P = .01, Cox proportional hazards regression: P = .0008). (C) OS of the 3 groups. (D) OS of Gem-Bu-Mel versus the combined Bu-Mel + BEAM groups (log-rank P = .04, Cox proportional hazards regression: P = .0005). Biology of Blood and Marrow Transplantation 2013 19, 410-417DOI: (10.1016/j.bbmt.2012.10.029) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Prognostic analysis of EFS. (A) PET and disease status at the time of HDC (Gem-Bu-Mel cohort). (B) Number of prior lines of salvage therapy (Gem-Bu-Mel). (C) Prior exposure/response to gemcitabine (Gem-Bu-Mel). (D) Pre- and post-HDC PET (Gem-Bu-Mel). (E) Disease status at HDC (Gem-Bu-Mel). (F) Disease status at HDC (combined Bu-Mel + BEAM group). Biology of Blood and Marrow Transplantation 2013 19, 410-417DOI: (10.1016/j.bbmt.2012.10.029) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 EFS comparisons across main patient subgroups. (A) Patients with PET-negative tumors at HDC. (B) Patients with PET-positive tumors. (C) Patients with 1 prior salvage treatment line. (D) Patients with >1 prior salvage treatment line. Biology of Blood and Marrow Transplantation 2013 19, 410-417DOI: (10.1016/j.bbmt.2012.10.029) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions